MRKMerck & Co Inc
Earnings Recap
• Reported GAAP EPS of -$1.72 down -185.57% YoY • Reported revenue of $16.29B up 4.87% YoY • Merck narrows and raises its full-year 2026 worldwide sales range to $65.8 billion to $67.0 billion, and expects non-GAAP EPS between $5.04 and $5.16, including a $3.62 per share charge for the Cidara acquisition. The Terns acquisition is not reflected.
Bullish
Merck's Q1 2026 sales increased, driven by strong growth in KEYTRUDA and WINREVAIR, significant regulatory approvals for IDVYNSO and ENFLONSIA, and positive clinical trial results, enhancing Merck's oncology and cardiometabolic pipelines.
Bearish
Merck reported a Q1 2026 GAAP loss per share of $1.72 due to a $3.62 charge for the Cidara acquisition, alongside significant sales declines in established products like GARDASIL and JANUVIA, and gross margin compression.